ACU vs SKIN

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for ACU just turned positive on October 22, 2026. Looking at past instances where ACU's MACD turned positive, the stock continued to rise in 43 of 61 cases over the following month. The odds of a continued upward trend are 70%.

ACU moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +2.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACU advanced for three days, in 160 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.

Bearish Trend Analysis

The 10-day RSI Indicator for ACU moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 16 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 64%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 72 cases where ACU's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 68%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.

ACU broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 14 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. ACU’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.161) is normal, around the industry mean (21.731). P/E Ratio (26.607) is within average values for comparable stocks, (16.288). Projected Growth (PEG Ratio) (0.140) is also within normal values, averaging (1.518). Dividend Yield (0.009) settles around the average of (0.032) among similar stocks. P/S Ratio (1.207) is also within normal values, averaging (1.902).

The Tickeron SMR rating for this company is 76 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on SKIN as a result. In 76 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.

SKIN moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for SKIN crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.

Following a +61.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where SKIN advanced for three days, in 191 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SKIN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

SKIN broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for SKIN entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (36.793) is normal, around the industry mean (21.731). SKIN has a moderately low P/E Ratio (-68.304) as compared to the industry average of (16.288). Projected Growth (PEG Ratio) (0.858) is also within normal values, averaging (1.518). Dividend Yield (0.000) settles around the average of (0.032) among similar stocks. P/S Ratio (0.302) is also within normal values, averaging (1.902).

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. SKIN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 44 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SKIN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.